Tuesday, 4 April 2017

Sarcopenia - Epidemiology Forecast To 2023 Market Report; Launched via MarketResearchReports.com

Sarcopenia - Epidemiology Forecast To 2023

Sarcopenia - Epidemiology Forecast To 2023 Report provides an overview of the epidemiology trends of Sarcopenia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023.

Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass after age 30, but the resulting loss of strength increases exponentially with age. Of the contributory factors relating to the development of sarcopenia inadequate protein intake, increased splanchnic extraction of amino acids, decreased muscular response to postprandial anabolic stimuli and vitamin D deficiency are directly related to nutrition.

According to Publisher, the prevalent cases of Sarcopenia in 7 MM are expected to increase and reach up to 42,969,489 cases by the end of year 2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Key Coverage and Benefits:
The report will help in developing business strategies by understanding the trends shaping and driving the global epidemiology of Sarcopenia.
Identifying prevalent patient populations as well as risk factors of Sarcopenia.

Spanning over 51 pages Sarcopenia - Epidemiology Forecast To 2023” report covers Report Introduction, Sarcopenia: Overview, Introduction, Sarcopenia categories and stages, Appendix.

For more information Visit at: http://mrr.cm/USD

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

No comments:

Post a Comment

Note: only a member of this blog may post a comment.